암 치료용 신규 약물전달 시스템 시장 예측( -2030년) : 약물 유형별, 딜리버리 방법별, 약물 방출 유형별, 기술별, 용도별, 최종사용자별, 지역별 세계 분석

According to Stratistics MRC, the Global Novel Drug Delivery Systems in Cancer Therapy Market is accounted for $18.38 billion in 2024 and is expected to reach $31.69 billion by 2030 growing at a CAGR of 9.5% during the forecast period. Advanced technologies created to improve the accurate and efficient distribution of cancer drugs to specific areas are referred to as novel drug delivery systems in cancer therapy. These systems, which include polymers, liposomes, and nanoparticles, are designed to decrease adverse effects, boost the bioavailability of medicinal compounds, and enhance treatment efficacy overall. These technologies provide promising options in cancer therapy by delivering medications directly to cancer cells or tumors, maximizing therapeutic efficacy while reducing harm to nearby healthy tissues.

Market Dynamics:

Driver:

Increased focus on personalized medicine

Growing emphasis on individualized care is a major factor propelling the market for novel drug delivery systems (NDDS) in cancer treatment. More accurate and efficient cancer treatments are made possible by personalized medicine, which adjusts treatment plans according to a patient's genetic composition, molecular profile, and tumor features. By making it easier to distribute medications to particular cancer cells, NDDS are essential to this strategy because they reduce harm to good tissue and improve therapy results. This accuracy lowers adverse effects and increases patient compliance with treatment plans. The creation of cutting-edge NDDS technology remains a vital part of contemporary cancer treatment plans, supporting market expansion as the need for tailored medicines increases.

Restraint:

High development costs

The sophisticated technologies needed for NDDS, like dendrimers, liposomes, and nanoparticles, require unique materials, intricate manufacturing procedures, and a great deal of experience. To guarantee the security and effectiveness of these systems, a great deal of preclinical and clinical testing is also required. Particularly in environments with limited resources, these exorbitant expenses may make it more difficult for smaller businesses to enter the market and may also lead to higher treatment costs, which would limit patient access. This means that the cost of developing NDDS prevents them from being widely adopted and commercialized.

Opportunity:

Growing research and development investments

The growing need for more effective, targeted, and personalized cancer treatments is driving an increase in research and development (R&D) investments in Novel Drug Delivery Systems (NDDS). R&D efforts are focused on developing advanced drug delivery technologies, such as nanoparticles, liposomes, and micelles, which enhance drug efficacy, minimize side effects, and improve patient compliance. Pharmaceutical and biotechnology companies are also investing heavily in innovative drug delivery systems to address the limitations of conventional therapies, such as poor bioavailability and systemic toxicity. Increased R&D investments accelerate the development of novel, more efficient, and safe drug delivery options for cancer treatment.

Threat:

Limited clinical evidence for certain delivery systems

Insufficient clinical data for specific Novel Drug Delivery Systems (NDDS) continues to be a major obstacle in the market for cancer treatments. Many NDDS methods, including specific nanoparticle formulations and gene-based delivery systems, have shown promise in preclinical research but have not yet proven to be consistently effective in human clinical trials. The widespread deployment of these technologies may be hampered by the potential delay in regulatory approval. For emerging NDDS technologies to succeed and be incorporated into standard cancer treatment, more thorough, extensive clinical trials are required to confirm the hazards and advantages of these technologies.

Covid-19 Impact

The COVID-19 pandemic has had a significant impact on the market for innovative drug delivery systems (NDDS) used in cancer treatment. The development and approval of new therapies have been delayed by disruptions in clinical trial procedures and supply chains. Cancer therapies also received less attention as a result of healthcare resources being redirected to COVID-19 management. Additionally, because cancer patients were more vulnerable during the pandemic, their treatment plans were more complex. This highlights the need for more efficient and focused medication delivery systems to improve patient outcomes in this difficult setting.

The chemotherapy drugs segment is expected to be the largest during the forecast period

The chemotherapy drugs segment is expected to account for the largest market share during the forecast period, due to their widespread use in cancer treatment. NDDS technologies enhance the effectiveness of chemotherapy by improving drug solubility, targeting cancer cells more precisely, and reducing systemic toxicity. These systems allow for controlled release, minimizing side effects and maximizing therapeutic impact. The growing need to improve chemotherapy outcomes while minimizing adverse effects fuels further development and integration of NDDS with chemotherapy agents.

The hospitals segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the hospitals segment is predicted to witness the highest growth rate, as primary centers for cancer treatment, hospitals are adopting advanced NDDS to enhance the efficacy of cancer therapies, reduce side effects, and improve patient outcomes. The increasing demand for personalized and targeted therapies in clinical settings pushes hospitals to invest in these innovative drug delivery systems, ultimately promoting their adoption and accelerating their integration into standard cancer treatment protocols.

Region with largest share:

During the forecast period, Asia Pacific region is expected to hold the largest market share, driven by rising cancer incidence, improving healthcare infrastructure, and increasing healthcare expenditure. Governments are investing in advanced medical technologies, while growing awareness of personalized medicine further boosts demand for NDDS. Additionally, the region's large patient population, combined with rapid advancements in biotechnology and pharmaceutical industries, positions Asia-Pacific as a key market for the development and adoption of innovative cancer treatment solutions.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to robust healthcare infrastructure, advanced research and development capabilities, and high healthcare spending. The region's focus on precision medicine, along with a growing emphasis on personalized cancer treatments, fuels demand for NDDS technologies. Additionally, regulatory support from agencies like the FDA, along with the presence of leading pharmaceutical and biotech companies accelerates the development and adoption of innovative drug delivery systems for cancer therapy in North America.

Key players in the market

Some of the key players profiled in the Novel Drug Delivery Systems in Cancer Therapy Market include Johnson & Johnson, Pfizer Inc., Novartis AG, Merck & Co., Inc., Roche Holding AG, Eli Lilly and Company, AbbVie Inc., Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Amgen Inc., Celgene Corporation, Bayer AG, Teva Pharmaceutical Industries Ltd., Gilead Sciences, Inc., Biocon Limited, and Mylan N.V.

Key Developments:

In June 2024, Bristol-Myers Squibb Company received FDA accelerated approval for KRAZATI (adagrasib) in combination with cetuximab, a targeted treatment for KRASG12C-mutated CRC patients who had undergone prior chemotherapy, based on ORR and DOR results.

In January 2024, Johnson & Johnson acquired Ambrx Biopharma, a clinical-stage biopharmaceutical company, in a cash merger deal valued at approximately USD 2.0 billion, with estimated cash on hand deducted.

Drug Types Covered:

• Chemotherapy Drugs
• Immunotherapy Drugs
• Targeted Therapy Drugs
• Hormonal Therapy Drugs
• Gene Therapy Drugs
• Other Drug Types

Delivery Methods Covered:

• Nanoparticle-Based Drug Delivery
• Microsphere-Based Drug Delivery
• Liposome-Based Drug Delivery
• Polymeric Drug Delivery
• Injection & Infusion Drug Delivery
• Implantable Drug Delivery Systems
• Other Delivery Methods

Drug Release Types Covered:

• Sustained Release
• Controlled Release
• Targeted Release

Technologies Covered:

• Nanotechnology
• Biotechnology
• Polymeric Drug Delivery Systems
• Liposomes and Nanoparticles
• Gene Therapy Delivery Systems
• Other Technologies

Applications Covered:

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Leukemia
• Other Applications

End Users Covered:

• Hospitals
• Cancer Research Institutes
• Specialty Clinics
• Home Care Settings
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Technology Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Novel Drug Delivery Systems in Cancer Therapy Market, By Drug Type

• 5.1 Introduction
• 5.2 Chemotherapy Drugs
• 5.3 Immunotherapy Drugs
• 5.4 Targeted Therapy Drugs
• 5.5 Hormonal Therapy Drugs
• 5.6 Gene Therapy Drugs
• 5.7 Other Drug Types

6 Global Novel Drug Delivery Systems in Cancer Therapy Market, By Delivery Method

• 6.1 Introduction
• 6.2 Nanoparticle-Based Drug Delivery
• 6.3 Microsphere-Based Drug Delivery
• 6.4 Liposome-Based Drug Delivery
• 6.5 Polymeric Drug Delivery
• 6.6 Injection & Infusion Drug Delivery
• 6.7 Implantable Drug Delivery Systems
• 6.8 Other Delivery Methods

7 Global Novel Drug Delivery Systems in Cancer Therapy Market, By Drug Release Type

• 7.1 Introduction
• 7.2 Sustained Release
• 7.3 Controlled Release
• 7.4 Targeted Release

8 Global Novel Drug Delivery Systems in Cancer Therapy Market, By Technology

• 8.1 Introduction
• 8.2 Nanotechnology
• 8.3 Biotechnology
• 8.4 Polymeric Drug Delivery Systems
• 8.5 Liposomes and Nanoparticles
• 8.6 Gene Therapy Delivery Systems
• 8.7 Other Technologies

9 Global Novel Drug Delivery Systems in Cancer Therapy Market, By Application

• 9.1 Introduction
• 9.2 Breast Cancer
• 9.3 Lung Cancer
• 9.4 Colorectal Cancer
• 9.5 Prostate Cancer
• 9.6 Leukemia
• 9.7 Other Applications

10 Global Novel Drug Delivery Systems in Cancer Therapy Market, By End User

• 10.1 Introduction
• 10.2 Hospitals
• 10.3 Cancer Research Institutes
• 10.4 Specialty Clinics
• 10.5 Home Care Settings
• 10.6 Other End Users

11 Global Novel Drug Delivery Systems in Cancer Therapy Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

• 13.1 Johnson & Johnson
• 13.2 Pfizer Inc.
• 13.3 Novartis AG
• 13.4 Merck & Co., Inc.
• 13.5 Roche Holding AG
• 13.6 Eli Lilly and Company
• 13.7 AbbVie Inc.
• 13.8 Bristol-Myers Squibb Company
• 13.9 Sanofi S.A.
• 13.10 AstraZeneca PLC
• 13.11 GlaxoSmithKline PLC
• 13.12 Amgen Inc.
• 13.13 Celgene Corporation
• 13.14 Bayer AG
• 13.15 Teva Pharmaceutical Industries Ltd.
• 13.16 Gilead Sciences, Inc.
• 13.17 Biocon Limited
• 13.18 Mylan N.V.